



# 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025

American Diabetes Association  
Professional Practice Committee\*

*Diabetes Care* 2025;48(Suppl. 1):S306–S320 | <https://doi.org/10.2337/dc25-S015>

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at [professional.diabetes.org/SOC](https://professional.diabetes.org/SOC).

## DIABETES IN PREGNANCY

The prevalence of diabetes in pregnancy has been increasing in the U.S. in parallel with the worldwide epidemic of obesity. Not only is the prevalence of type 1 diabetes and type 2 diabetes increasing in individuals of reproductive age but there is also a dramatic increase in the reported rates of gestational diabetes mellitus (GDM). Diabetes confers significantly greater maternal and fetal risk that is largely related to the degree of hyperglycemia but also is related to chronic complications and comorbidities of diabetes. In general, specific risks of diabetes in pregnancy include spontaneous abortion, fetal anomalies, preeclampsia, fetal demise, macrosomia, neonatal hypoglycemia, neonatal hyperbilirubinemia, and neonatal respiratory distress syndrome. In addition, exposure to hyperglycemia in utero increases the risks of obesity, hypertension, and type 2 diabetes in offspring later in life (1,2).

### Preconception Counseling

#### Recommendations

**15.1** Starting at puberty and continuing in all people with diabetes and child-bearing potential, preconception counseling should be incorporated into routine diabetes care. **A**

**15.2** Family planning should be discussed, and effective contraception (with consideration of long-acting, reversible contraception) should be prescribed and used until an individual’s treatment plan and A1C are optimized for pregnancy. **A**

**15.3** Preconception counseling should address the importance of achieving glucose levels as close to normal as is safely possible, ideally A1C <6.5% (<48 mmol/mol), to reduce the risk of congenital anomalies, preeclampsia, macrosomia, preterm birth, and other complications. **A**

\*A complete list of members of the American Diabetes Association Professional Practice Committee can be found at <https://doi.org/10.2337/dc25-SINT>.

Duality of interest information for each author is available at <https://doi.org/10.2337/dc25-SDIS>.

Suggested citation: American Diabetes Association Professional Practice Committee. 15. Management of diabetes in pregnancy: Standards of Care in Diabetes—2025. *Diabetes Care* 2025;48(Suppl. 1): S306–S320

© 2024 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/journals/pages/license>.

**15.4** Individuals with a history of gestational diabetes mellitus (GDM) should seek preconception screening for diabetes and preconception care to identify and treat hyperglycemia and prevent congenital malformations. **E**

Preconception counseling for pregnant people with preexisting type 1 or type 2 diabetes is highly effective in reducing the risk of congenital malformations and decreasing the risk of preterm delivery and admission to neonatal intensive care units. Preconception counseling is also associated with reductions in perinatal mortality and small-for-gestational-age birth weight (3). A key point is the need to incorporate a question about plans for pregnancy into the routine primary and gynecologic care of people with diabetes.

There are opportunities at any health care visit to educate all adults and adolescents with diabetes and childbearing potential about the risks of unplanned pregnancies and about improved maternal and fetal outcomes with pregnancy planning (4). Education and counseling should be offered, even when individuals already use contraception or do not intend to conceive (5). Effective preconception counseling could avert substantial health and associated cost burdens related to the offspring (6). Family planning should be discussed, including the benefits of long-acting, reversible contraception, and effective contraception should be prescribed and used until the individual is prepared and ready to become pregnant (7–11).

All individuals with diabetes and childbearing potential should be informed about the importance of achieving and maintaining as near euglycemia as safely possible prior to conception and throughout pregnancy. Observational studies show an increased risk of diabetic embryopathy, especially anencephaly, microcephaly, congenital heart disease, kidney anomalies, and caudal regression, directly proportional to elevations in A1C during the first 10 weeks of pregnancy (12). Although observational studies are confounded by the association between elevated periconceptional A1C and other engagement in self-care behaviors, the quantity and consistency of data are convincing and support the recommendation to optimize glycemia prior to conception with an A1C <6.5% (<48 mmol/mol), as this

is associated with the lowest risk of congenital anomalies (given that organogenesis occurs primarily at 5–8 weeks of gestation), preeclampsia, and preterm birth (12–16). In a systematic review and meta-analysis of observational studies, preconception care for pregnant individuals with preexisting diabetes was associated with lower A1C and reduced risks of birth defects, preterm delivery, perinatal mortality, small-for-gestational-age births, and neonatal intensive care unit admissions (17).

To minimize the occurrence of complications, beginning at the onset of puberty or at diagnosis, all adults and adolescents with diabetes of childbearing potential should receive education about 1) the risks of malformations associated with unplanned pregnancies, even with mild hyperglycemia, and 2) the use of effective contraception at all times when trying to prevent a pregnancy. Preconception counseling using developmentally appropriate educational tools enables adolescents with childbearing potential to make well-informed decisions (4). Preconception counseling resources tailored to adolescents are available at no cost through the American Diabetes Association (ADA) (18).

Individuals with prediabetes or a history of GDM will need preconception evaluation for as long as they have childbearing potential. Individuals with a history of GDM who are planning pregnancy should undergo screening for prediabetes or type 2 diabetes prior to conception, as outlined in Section 2, “Diagnosis and Classification of Diabetes.” In the nonpregnant state, evaluation may be performed with any glycemic test recommended in Section 2. If the evaluation reveals euglycemia without prediabetes or type 2 diabetes, then with a subsequent pregnancy the individual with GDM should be screened for abnormal glucose metabolism (<15 weeks) or GDM at 24–28 weeks (if abnormal glucose metabolism testing was not previously performed or was not present) as outlined in Section 2. Should prediabetes or type 2 diabetes be diagnosed, the individual should initiate treatment with a goal to achieve and maintain an A1C of <6.5% (<48 mmol/mol) prior to conception using therapies approved for use in pregnancy. Preconception evaluation should assess maternal weight. In a randomized trial of individuals with overweight or obesity and a history of GDM, weight loss prior to a subsequent pregnancy was associated with a lower risk of GDM recurrence,

especially when weight loss was  $\geq 5\%$  (odds ratio [OR] 0.18, 95% CI 0.04–0.88) (19). Counseling on weight management should include the known benefits and risks of different strategies for achieving and maintaining weight loss. For strategies that include pharmacotherapy, recommendations should be given for when changes in medications should occur prior to pregnancy.

## Preconception Care

### Recommendations

**15.5** Individuals with preexisting diabetes who are planning a pregnancy should ideally begin receiving interprofessional care for preconception, which includes an endocrinology health care professional, maternal-fetal medicine specialist, registered dietitian nutritionist, and diabetes care and education specialist, when available. **B**

**15.6** In addition to focused attention on achieving glycemic goals, **A** standard preconception care should be augmented with extra focus on nutrition, physical activity, diabetes self-care education, and screening for diabetes comorbidities and complications. **B**

**15.7** Individuals with preexisting diabetes who are planning a pregnancy or who have become pregnant should be counseled on the risk of development and/or progression of diabetic retinopathy. Dilated eye examinations should occur ideally before pregnancy as well as in the first trimester, and then pregnant individuals should be monitored every trimester and for 1 year postpartum as indicated by the degree of retinopathy and as recommended by the eye care health care professional. **B**

The importance of preconception care for all pregnant people is highlighted by American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 762, “Pregncancy Counseling” (5). Preconception care for people with prediabetes and diabetes should include the standard screening and care recommended for any person planning pregnancy (5). Prescription of prenatal vitamins with at least 400–800  $\mu\text{g}$  of folic acid (20) and 150 mg of potassium iodide (21) is recommended prior to conception. Review and counseling on abstaining from nicotine products, alcohol, and recreational drugs, including marijuana, is important. Standard

care includes screening for sexually transmitted infections and thyroid disease, recommended vaccinations, routine genetic screening, a careful review of all prescription and nonprescription medications, herbal supplements, and nonherbal supplements used and a review of travel history and plans with special attention on areas known to have relevant endemic viruses, as outlined by ACOG. See **Table 15.1** for additional details on elements of preconception care (5,20,22).

Due to the complexity of insulin management in pregnancy, referral to a specialized center offering team-based care (with team members including a maternal-fetal medicine specialist, endocrinologist or other health care professional experienced in managing pregnancy and preexisting diabetes, registered dietitian nutritionist (RDN), diabetes care and education specialist, and social worker, as needed) is recommended if this resource is available. When a single specialized center is not available, providing an interprofessional team approach through interprofessional team members at different centers may still be beneficial.

The most important diabetes-specific component of preconception care is the attainment of glycemic goals prior to conception. Diabetes-specific counseling should include an explanation of the risks to mother and fetus related to pregnancies associated with diabetes and the ways to reduce risks, including glycemic goal setting, lifestyle and behavioral management, and medical nutrition therapy (3). Risks for GDM are characterized by an increased risk of large-for-gestational-age birth weight and neonatal and pregnancy complications and an increased risk of long-term maternal type 2 diabetes and abnormal glucose metabolism of offspring in childhood. These associations with maternal oral glucose tolerance test (OGTT) results are continuous with no clear inflection points (23,24). Offspring with exposure to untreated GDM have reduced insulin sensitivity and  $\beta$ -cell compensation and are more likely to have impaired glucose tolerance in childhood (25). In other words, short-term and long-term risks increase with progressive maternal hyperglycemia.

Counseling on the specific risks of obesity in pregnancy and lifestyle interventions to prevent and treat obesity, including referral to an RDN, is recommended regardless of diabetes status (26). The risk for associated hypertension and other comorbidities may be as high or higher with type 2

**Table 15.1—Checklist for preconception care for people with prediabetes, diabetes, or a history of gestational diabetes mellitus**

**Preconception education should include:**

- Comprehensive nutrition assessment and recommendations for:
  - Overweight and obesity or underweight
  - Meal planning
  - Correction of dietary nutritional deficiencies
  - Caffeine intake
  - Safe food preparation technique
- Lifestyle recommendations for:
  - Regular moderate exercise
  - Avoidance of hyperthermia (hot tubs)
  - Adequate sleep
- Comprehensive diabetes self-management education
- Counseling on diabetes in pregnancy per current standards, including natural history of insulin resistance in pregnancy and postpartum; preconception glycemic goals; avoidance of DKA and severe hyperglycemia; avoidance of severe hypoglycemia; progression of retinopathy in individuals with preexisting diabetes; PCOS (if applicable); fertility in people with diabetes; genetics of diabetes; risks to pregnancy including miscarriage, stillbirth, congenital malformations, macrosomia, preterm labor and delivery, hypertensive disorders in pregnancy
- Supplementation
  - Folic acid supplement (400–800  $\mu$ g/day routine)
  - Appropriate use of over-the-counter medications and supplements

**Health assessment and plan should include:**

- General evaluation of overall health
- Evaluation of diabetes and its comorbidities and complications, including DKA and severe hyperglycemia; severe hypoglycemia/hypoglycemia unawareness; barriers to care; comorbidities such as hyperlipidemia, hypertension, MASLD, PCOS, and thyroid dysfunction; complications such as macrovascular disease in individuals with preexisting diabetes, nephropathy, neuropathy (including autonomic bowel and bladder dysfunction), and retinopathy
- Evaluation of obstetric or gynecologic history, including a history of cesarean section, congenital malformations or fetal loss, current methods of contraception, hypertensive disorders of pregnancy, postpartum hemorrhage, preterm delivery, previous macrosomia, Rh incompatibility, and thrombotic events (DVT/PE)
- Review of current medications and appropriateness during pregnancy

**Screening should include:**

- Diabetes complications and comorbidities in individuals with preexisting diabetes, including comprehensive foot exam; comprehensive ophthalmologic exam; ECG in individuals starting at age 35 years who have cardiac signs or symptoms or risk factors and, if abnormal, further evaluation; lipid panel; serum creatinine; TSH; and urine albumin-to-creatinine ratio
- Anemia
- Genetic carrier status (based on history):
  - Cystic fibrosis
  - Sickle cell anemia
  - Tay-Sachs disease
  - Thalassemia
  - Others if indicated
- Infectious disease (per ACOG guidelines)

**Preconception plan should include:**

- Immunizations (per ACOG guidelines) (165–167)
- Nutrition and medication plan to achieve glycemic goals prior to conception, including appropriate implementation of blood glucose monitoring, continuous glucose monitoring (if indicated and appropriate), and pump technology (if indicated and appropriate)
- Contraceptive plan to prevent pregnancy until glycemic goals are achieved
- Management plan for general health, gynecologic concerns, comorbid conditions, or complications, if present, including hypertension, nephropathy, retinopathy; Rh incompatibility; and thyroid dysfunction

Created using information from American College of Obstetricians and Gynecologists (ACOG) (5) and others (20,22). DKA, diabetic ketoacidosis; DVT/PE, deep vein thrombosis/pulmonary embolism; ECG, electrocardiogram; MASLD, metabolic dysfunction-associated steatotic liver disease; PCOS, polycystic ovary syndrome; TSH, thyroid-stimulating hormone.

diabetes as it is with type 1 diabetes, even if diabetes is better managed and of shorter apparent duration, with pregnancy loss appearing to be more prevalent in the third trimester in those with type 2 diabetes compared with the

first trimester in those with type 1 diabetes (27,28).

For individuals with preexisting diabetes, the presence of microvascular complications is associated with higher risk of disease progression and adverse pregnancy outcomes (29). Diabetes-specific testing should include A1C, creatinine, and urinary albumin-to-creatinine ratio. Special attention should be paid to the review of the medication list for potentially harmful drugs, e.g., ACE inhibitors (30), angiotensin receptor blockers (30), and statins in some cases (31). For individuals using medications that are not approved for use in pregnancy (such as some glucose-lowering, lipid-lowering, and antihypertensive agents), preconception care should include recommendations for when changes in medications should occur to stabilize the conditions and risk factors managed by these medications (such as glucose levels, weight, lipids, and blood pressure) on alternate therapies prior to pregnancy. A referral for a comprehensive eye exam is recommended. Individuals with preexisting diabetic retinopathy will need close monitoring during pregnancy to assess stability or progression of retinopathy and provide treatment if indicated (32).

## GLYCEMIC GOALS IN PREGNANCY

### Recommendations

**15.8** Fasting, preprandial, and postprandial blood glucose monitoring are recommended in individuals with diabetes in pregnancy to achieve optimal glucose levels. Glucose goals are fasting plasma glucose <95 mg/dL (<5.3 mmol/L) and either 1-h postprandial glucose <140 mg/dL (<7.8 mmol/L) or 2-h postprandial glucose <120 mg/dL (<6.7 mmol/L). **B**

**15.9** Due to increased red blood cell turnover, A1C is slightly lower during pregnancy in people with and without diabetes. Ideally, the A1C goal in pregnancy is <6% (<42 mmol/mol) if this can be achieved without significant hypoglycemia, but the goal may be relaxed to <7% (<53 mmol/mol) if necessary to prevent hypoglycemia. **B**

**15.10** Continuous glucose monitoring (CGM) can help to achieve glycemic goals (e.g., time in range, time above range) **A** and A1C goal **B** in type 1 diabetes and pregnancy and may be

beneficial for other types of diabetes in pregnancy. **E**

**15.11** Recommend CGM to pregnant individuals with type 1 diabetes. **A** In conjunction with aims to achieve traditional pre- and postprandial glycemic goals, real-time CGM can reduce the risk for large-for-gestational-age infants and neonatal hypoglycemia in pregnancy complicated by type 1 diabetes. **A**

**15.12** CGM metrics may be used in combination with blood glucose monitoring to achieve optimal pre- and postprandial glycemic goals. **E**

**15.13** Commonly used estimated A1C and glucose management indicator calculations should not be used in pregnancy as estimates of A1C. **C**

### Insulin Physiology

Pregnancy in people with normal glucose metabolism is characterized by fasting levels of blood glucose that are lower than those in the nonpregnant state due to insulin-independent glucose uptake by the fetus and placenta and by mild postprandial hyperglycemia and carbohydrate intolerance as a result of diabetogenic placental factors. Early pregnancy may be a time of enhanced insulin sensitivity and lower glucose levels and is followed by progressive insulin resistance in the second and third trimesters (33–35). Insulin resistance drops rapidly with the delivery of the placenta. In people with normal pancreatic function, insulin production is sufficient to meet the challenge of this physiological insulin resistance and to maintain normal glucose levels. However, in people with diabetes, hyperglycemia occurs if treatment is not adjusted appropriately.

### Glucose Monitoring

Reflecting this physiology, fasting and postprandial blood glucose monitoring is recommended to achieve glycemic goals in pregnant people with diabetes. Preprandial testing is also recommended when using insulin pumps or basal-bolus therapy so that the premeal rapid-acting insulin dosage can be adjusted. Postprandial monitoring is associated with better glycemic outcomes and a lower risk of preeclampsia (36–38). There are no adequately powered randomized trials comparing different fasting and postmeal glycemic goals for preexisting diabetes in pregnancy.

Similar to the glycemic goals recommended by ACOG (39), the ADA-recommended goals for pregnant people with type 1 or type 2 diabetes are shown in **Table 15.2**. Lower limits are based on the mean of normal blood glucose in pregnancy (40) but do not apply to individuals with type 2 diabetes treated with nutrition alone. Hypoglycemia in pregnancy is as defined and discussed in Recommendations 6.10–6.18 (see Section 6, “Glycemic Goals and Hypoglycemia”). The most appropriate hypoglycemia threshold level in pregnancy has not been validated but has ranged from <60 to <70 mg/dL (<3.3 to <3.9 mmol/L) in the past. Current recommendations for hypoglycemia thresholds include blood glucose <70 mg/dL (<3.9 mmol/L) and sensor glucose <63 mg/dL (<3.5 mmol/L) (40,41). These fasting or premeal and postprandial glucose values represent optimal levels if they can be achieved safely. In practice, it may be challenging for a person with type 1 diabetes to achieve these goals without hypoglycemia, particularly those with a history of recurrent hypoglycemia or impaired awareness of hypoglycemia. If an individual cannot achieve these goals without significant hypoglycemia, aim for less stringent goals based on clinical experience and individualization of care.

For individuals with GDM, glucose monitoring should aim for the goals recommended by the Fifth International Workshop-Conference on Gestational Diabetes Mellitus (42) (**Table 15.2**).

### A1C in Pregnancy

In studies of individuals without preexisting diabetes, increasing A1C levels within the normal range are associated with adverse outcomes (43). In the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, increasing levels of glycemia were also associated with worsening outcomes (23). Observational studies in preexisting diabetes and pregnancy show the lowest rates of adverse fetal outcomes in association with A1C <6–6.5% (<42–48 mmol/mol) early in gestation (13,14,16,44). Clinical trials have not evaluated the risks and benefits of achieving these goals, and treatment goals should account for the risk of maternal hypoglycemia in setting an individualized goal of <6% (<42 mmol/mol) to

**Table 15.2—Blood glucose goals in pregnancies associated with diabetes**

Glucose measurement	Blood glucose goal		
	Type 1 diabetes or type 2 diabetes <sup>^</sup>	GDM treated with insulin	GDM not treated with insulin
Fasting glucose	70–95 mg/dL (3.9–5.3 mmol/L)	70–95 mg/dL (3.9–5.3 mmol/L)	<95 mg/dL (<5.3 mmol/L)
1-h postprandial glucose	110–140 mg/dL* (6.1–7.8 mmol/L)	110–140 mg/dL* (6.1–7.8 mmol/L)	<140 mg/dL* (<7.8 mmol/L)
2-h postprandial glucose	100–120 mg/dL (5.6–6.7 mmol/L)	100–120 mg/dL (5.6–6.7 mmol/L)	<120 mg/dL (<6.7 mmol/L)

Gestational diabetes mellitus (GDM) blood glucose goals shown are recommended by the Fifth International Workshop-Conference on Gestational Diabetes Mellitus (42). <sup>^</sup>Lower glucose limits do not apply to individuals with type 2 diabetes treated with nutrition alone. Aim for less stringent goals if these cannot be achieved without significant hypoglycemia, based on clinical experience and individualization of care.

\*Optimal goal includes either a 1-h postprandial glucose level or 2-h postprandial glucose level within column of type of diabetes.

<7% (<53 mmol/mol). Due to physiological increases in red blood cell turnover, A1C levels fall during normal pregnancy (45,46). Additionally, as A1C represents an integrated measure of glucose, it may not fully capture postprandial hyperglycemia, which drives macrosomia. Thus, although A1C may be useful, it should be used as a secondary measure of glycemic outcomes in pregnancy, after blood glucose monitoring.

In the second and third trimesters, A1C <6% (<42 mmol/mol) has the lowest risk of large-for-gestational-age infants (44,47,48), preterm delivery (49), and preeclampsia (1,50). Taking all of this into account, a goal of <6% (<42 mmol/mol) is optimal during pregnancy if it can be achieved without significant hypoglycemia, which, in addition to the usual adverse sequelae, may increase the risk of low birth weight (51,52). Given the alteration in red blood cell kinetics during pregnancy and physiological changes in glycemic parameters, A1C levels may need to be monitored more frequently than usual (e.g., monthly).

### Continuous Glucose Monitoring in Pregnancy

The Continuous Glucose Monitoring in Pregnant Women With Type 1 Diabetes Trial (CONCEPTT) was a randomized controlled trial (RCT) of real-time continuous glucose monitoring (CGM) in addition to standard care, including optimization of pre- and postprandial glucose goals versus standard care for pregnant people with type 1 diabetes. It demonstrated the value of using real-time CGM in pregnant individuals with type 1 diabetes by showing a mild improvement in A1C and significant improvements in the maternal glucose time in range (TIR) and time above range

(TAR), without an increase in hypoglycemia, and reductions in large-for-gestational-age births, length of infant hospital stays, and severe neonatal hypoglycemia (53). An observational cohort study that evaluated the glycemic variables reported using CGM systems found that lower mean glucose, lower SD, and higher percentage of TIR were associated with lower risks of large-for-gestational-age births and other adverse neonatal outcomes (54). Data from one study suggest that the use of the CGM-reported mean glucose is superior to the use of estimated A1C, glucose management indicator, and other calculations to estimate A1C, given the changes to A1C that occur in pregnancy (55). One RCT and two observational studies have found that a 5% increase in CGM TIR was associated with improvements in neonatal morbidity, including large-for-gestational-age births and neonatal intensive care unit admissions (53,54,56). CGM TIR can be used for assessment of glycemic outcomes in people with type 1 diabetes, but it does not provide actionable data to address fasting and postprandial hypoglycemia or hyperglycemia. The cost of CGM use by pregnant individuals with type 1 diabetes is offset by improved maternal and neonatal outcomes (57).

There are insufficient data to support the use of CGM in all people with type 2 diabetes or GDM (58,59). The decision of whether to use CGM in pregnant individuals with type 2 diabetes or GDM should be individualized based on treatment plan, circumstances, preferences, and needs.

The international consensus on TIR (41) endorses pregnancy glucose goal ranges and goals for TIR for people with type 1 diabetes using CGM as reported on the ambulatory glucose profile. The international consensus on TIR (41)

endorses the same sensor glucose goal ranges for individuals with type 2 diabetes in pregnancy and GDM but could not quantify the goal of amount of time spent within each category because of insufficient data. However, the consensus does not specify the type or accuracy of the CGM device or need for alarms and alerts. A small prospective, observational study of pregnant people with type 1 diabetes simultaneously monitored with intermittently scanning CGM (isCGM) and real-time CGM for 7 days in early pregnancy demonstrated a higher percentage of time below range (TBR) in the isCGM group. Asymptomatic hypoglycemia measured by isCGM should therefore not necessarily lead to a reduction of insulin dose and/or increased carbohydrate intake at bedtime unless these episodes are confirmed by blood glucose meter measurements (60). Selection of CGM device should be based on an individual's circumstances, preferences, and needs.

Goals for sensor glucose ranges in pregnancy:

- Goal sensor glucose range 63–140 mg/dL (3.5–7.8 mmol/L): TIR, goal >70%
- TBR (<63 mg/dL [<3.5 mmol/L]): level 1 TBR, goal <4%
- TBR (<54 mg/dL [<3.0 mmol/L]): level 2 TBR, goal <1%
- TAR (>140 mg/dL [>7.8 mmol/L]): TAR, goal <25%

Goals for time spent in each range are specific for pregnant individuals with type 1 diabetes.

### MANAGEMENT OF DIABETES IN PREGNANCY

#### Recommendations

**15.14** Nutrition counseling before and during pregnancy should promote an

eating pattern including fruits, vegetables, legumes, whole grains, nuts, seeds, fish, and other lean protein, which will provide a balance of macronutrients and healthy n-3 fatty acids. **C**

**15.15** Lifestyle behavior change is an essential component of management of GDM and may suffice as treatment for many individuals. Insulin should be added if needed to achieve glycemic goals. **A**

**15.16** Telehealth visits used in combination with in-person visits for pregnant people with GDM can improve outcomes compared with standard in-person care alone. **A**

**15.17** Insulin should be used to manage type 1 diabetes in pregnancy **A** and is the preferred agent for the management of GDM **A** and type 2 diabetes in pregnancy. **B**

**15.18** Either multiple daily injections or insulin pump technology can be used in pregnancy complicated by type 1 diabetes. **C**

**15.19** Automated insulin delivery (AID) systems with pregnancy-specific glucose targets are recommended for pregnant individuals with type 1 diabetes. **A**

**15.20** AID systems without pregnancy-specific glucose targets or a pregnancy-specific algorithm may be considered for select pregnant individuals with type 1 diabetes when used with assistive techniques and working with experienced health care teams. **B**

**15.21** Metformin and glyburide, individually or in combination, should not be used as first-line agents for management of diabetes in pregnancy, as both cross the placenta to the fetus **A** and may not be sufficient to achieve glycemic goals. **B** Other oral and noninsulin injectable glucose-lowering medications lack long-term safety data and are not recommended. **E**

**15.22** Metformin, when used to treat polycystic ovary syndrome and induce ovulation, should be discontinued by the end of the first trimester. **A**

The management of pregnancies associated with diabetes includes appropriate nutrition, lifestyle and behavior management, physical activity goals, and pharmacotherapy to support the maternal, fetal, and placental needs and reach glycemic goals regardless of the diabetes type.

### Medical Nutrition Therapy

In people with preexisting diabetes, glycemic goals are usually achieved through a combination of insulin administration and medical nutrition therapy. Because glycemic goals in pregnant individuals are stricter than in nonpregnant individuals, it is important that pregnant people with diabetes eat consistent amounts of carbohydrates to match their insulin dosage and to avoid hyperglycemia or hypoglycemia. Referral to an RDN is important to establish a food plan and insulin-to-carbohydrate ratio and determine weight gain goals. The quality of the carbohydrates should be evaluated. A subgroup analysis of the CONCEPTT study demonstrated that the diets of individuals planning pregnancy and currently pregnant assessed during the run-in phase prior to randomization were characterized by high-fat, low-fiber, and poor-quality carbohydrate intakes. Fruit and vegetable consumption was inadequate, with one in four participants at risk for micronutrient deficiencies, highlighting the importance of medical nutrition therapy (61).

An expert panel on nutrition in pregnancy and the U.S. Department of Health and Human Services recommend a balance of macronutrients. An eating pattern that severely restricts any macronutrient class should be avoided, specifically the ketogenic diet that lacks carbohydrates, the paleo diet because of dairy restriction, and any eating pattern characterized by excess saturated fats (62). Pregnant individuals with diabetes are recommended to consume whole foods, including fruits, vegetables, legumes, whole grains, lean protein, and healthy fats with n-3 fatty acids, which includes nuts and seeds and fish, which are less likely to promote excessive weight gain (63). Processed foods, fatty red meat, and sweetened foods and beverages should be limited (62,63).

The recommended dietary reference intake for all pregnant people is a minimum of 175 g of carbohydrate (~35% of a 2,000-calorie diet), a minimum of 71 g of protein, and 28 g of fiber (64). The nutrition plan should emphasize monounsaturated and polyunsaturated fats while limiting saturated fats and avoiding *trans* fats. As is true for all nutrition therapy in people with diabetes, the amount and type of carbohydrate will impact glucose levels. Promoting

higher-quality, nutrient-dense carbohydrates results in ability to meet fasting or postprandial glucose goals, lower free fatty acids, improved insulin action, and vascular benefits and may reduce excess infant adiposity. Individuals who substitute fat for carbohydrates may unintentionally enhance lipolysis, promote elevated free fatty acids, and worsen maternal insulin resistance (65,66). Fasting urine ketone testing may be useful to identify those who are severely restricting carbohydrates to manage blood glucose. Carbohydrate restriction can increase the risk of higher dietary fat consumption, which may lead to fetal overgrowth (62). Simple carbohydrates will result in higher postmeal excursions.

Medical nutrition therapy for GDM is an individualized nutrition plan developed between the pregnant person and an RDN familiar with the management of GDM (67,68). The food plan should provide adequate calorie intake to promote fetal, neonatal, and maternal health, achieve glycemic goals, and promote appropriate weight gain, according to the 2009 National Academy of Medicine recommendations (69). There is no definitive research that identifies a specific optimal calorie intake for people with GDM or suggests that their calorie needs are different from those of pregnant individuals without GDM. The food plan should be based on a nutrition assessment with dietary reference intake guidance from the National Academy of Medicine.

### Lifestyle and Behavioral Management

Although there is some heterogeneity, many RCTs and a Cochrane review suggest that the risk of GDM may be reduced by diet, exercise, and lifestyle counseling, particularly when interventions are started during the first trimester or early in the second trimester (70–72).

After diagnosis of GDM, treatment starts with medical nutrition therapy, physical activity, and weight management, depending on pregestational weight, as outlined in this section. Depending on the population, studies suggest that 70–85% of people diagnosed with GDM under Carpenter-Coustan criteria can manage GDM with lifestyle modification alone; it is anticipated that this proportion will be even higher if the lower International Association of the Diabetes and Pregnancy Study Groups (73) diagnostic thresholds are used.

### Physical Activity

It is recommended that generally healthy people do at least 150 min of moderate-intensity aerobic activity each week during pregnancy and postpartum, preferably spread throughout the week (74). Adjustments to a physical activity routine or plan should be done in consultation with a health care professional, especially if someone is considering a big change in physical activity intensity (74). Such activity improves cardiorespiratory fitness and reduces the risk for excessive gestational weight gain or postpartum weight retention (74).

With respect to GDM, a systematic review demonstrated improvements in glucose outcomes and reductions in need to start insulin or insulin dose requirements with an exercise intervention. However, there was heterogeneity in the types of effective exercise (aerobic, resistance, or both) and duration of exercise (20–50 min/day, 2–7 days/week of moderate intensity) (75), so there is insufficient evidence about which specific type of exercise program has the biggest impact on these diabetes-related outcomes in pregnancy.

### Health Care Delivery for People With Diabetes in Pregnancy

As discussed in the preconception care subsection above, team-based care is recommended either through a single specialized center (when available) or multiple centers with interprofessional team members as part of the care plan during pregnancy. A meta-analysis of 32 RCTs evaluating the effectiveness of telemedicine interventions, which ranged from telemedicine visits to the use of health apps, used in combination with in-person visits for GDM demonstrated reduced incidences of cesarean delivery, premature rupture of membranes, pregnancy-induced hypertension or preeclampsia, preterm birth, neonatal asphyxia, and polyhydramnios compared with standard in-person care alone (76).

### Pharmacologic Therapy

#### Insulin

Insulin should be used to manage type 1 diabetes in pregnancy and is preferred for the management of type 2 diabetes in pregnancy and GDM. The physiology of pregnancy necessitates frequent titration of insulin to match changing requirements and underscores the importance of daily and frequent blood glucose monitoring. In early pregnancy, many people with type 1

diabetes will have lower insulin requirements and an increased risk for hypoglycemia (33). At around 16 weeks, insulin resistance begins to increase, and total daily insulin doses increase linearly by ~5% per week through week 36. This usually results in a doubling of daily insulin dose compared with the prepregnancy requirement. While there is an increase in both basal and bolus insulin requirements, bolus insulin requirements take up a larger proportion of overall total daily insulin needs in individuals with preexisting diabetes as pregnancy progresses (34,35). The insulin requirement levels off toward the end of the third trimester. A rapid and significant reduction in insulin requirements may indicate the development of placental insufficiency (36), although data are conflicting (77).

Optimal glycemic goals are often easier to achieve during pregnancy with type 2 diabetes than with type 1 diabetes but can require much higher doses of insulin, sometimes necessitating concentrated insulin formulations. It is recommended that insulin management be performed with interprofessional team members with relevant expertise.

None of the currently available human insulin preparations have been demonstrated to cross the placenta (78–83). Insulins studied in RCTs are preferred (84–86) over those studied in cohort studies (87), which are preferred over those studied in case reports only.

Both multiple daily insulin injections and continuous subcutaneous insulin infusion are reasonable delivery strategies in pregnancy, with neither showing superiority over the other (82,88). Partial closed-loop therapy, such as predictive low-glucose suspend (PLGS) technology, has been shown in nonpregnant people to be better than sensor-augmented insulin pumps (SAP) for reducing low glucose values (89). It may be suited for pregnancy because predictive low-glucose thresholds for suspending insulin are in the pregnancy ranges of premeal and overnight glucose goals and may allow for more aggressive prandial dosing.

Automated insulin delivery (AID) systems have been studied in pregnancy and postpartum. In one study, 124 pregnant individuals with type 1 diabetes used either an AID system with glucose targets that could be set near or in the

pregnancy-specific fasting glucose range or standard of care (CGM use with another insulin delivery strategy). Investigators recommended pump glucose targets of 100 mg/dL in early pregnancy and 81–90 mg/dL from 16 to 20 weeks onward. The AID group had a higher CGM TIR (10.5% difference between groups,  $P < 0.001$ ), lower TAR (–10.2% [95% CI –13.8 to –6.6]), and lower A1C (–0.31% [–0.50 to –0.12]), and a subset of participants who were interviewed reported benefits with AID use during pregnancy (e.g., more enjoyment of pregnancy, better sleep, less worry) (90,91).

There have been RCTs examining AID systems that do not have either pregnancy-specific pump glucose targets in the algorithms or algorithms that adapt specifically to pregnancy but were used with assistive techniques. In a study with 95 pregnant individuals with type 1 diabetes, participants used an AID system set to a pump glucose target of 100 mg/dL or to standard of care. The 24-h TIR was similar between groups, but the nocturnal TIR was higher (6.58%,  $P = 0.003$ ), the 24-h TBR was lower (–1.34%,  $P = 0.002$ ), and the nocturnal TBR was lower (–1.86%,  $P = 0.0005$ ) in the AID group (92). AID users reported higher diabetes treatment satisfaction and had less hypoglycemia unawareness (per Gold scores) (92). In a pilot study ( $n = 23$ ) where participants were randomized in the second trimester to AID with a system whose glucose target is 120 mg/dL or SAP with the same system, time spent in TBR decreased significantly in the AID group from baseline to third trimester (7.5% first trimester vs. 2.8% third trimester,  $P < 0.05$ ), but the average sensor glucose was higher in the AID group in the third trimester (mean [SE] 119 [4] SAP vs. 132 [4] AID,  $P = 0.0475$ ) without significant differences between groups in other CGM metrics (93). These two studies used assistive techniques, such as administration of fake carbohydrate insulin boluses for carbohydrates that were not consumed, and pump management was determined by expert guidance from an experienced interprofessional team (92–94). Thus, it may be appropriate to continue or initiate AID therapy with systems that do not have pregnancy-specific glucose targets or algorithms in carefully selected pregnant individuals with type 1 diabetes in the setting

of using assistive techniques with expert guidance (92–94). Assessments of potential candidates for AID wear in pregnancy should include relevant parameters such as glycemic levels, presence or absence of severe hypoglycemic or hyperglycemic events, ability or comfort in engaging with diabetes technology, psychosocial determinants, cost, individual preference, and other factors as relevant.

Continuous subcutaneous insulin infusion was compared with intravenous insulin infusion in an RCT of 70 participants during labor and delivery. There was no difference between groups in the primary outcome of neonatal hypoglycemia or in secondary outcomes (e.g., mean neonatal glucose in first 24 h of life, severe neonatal hypoglycemia) (95). In an RCT of 18 participants using AID or sensor-augmented pump therapy for 12 weeks postpartum (96), those in the AID group had fewer hypoglycemia episodes (96). See sensor-augmented pumps and automated insulin delivery systems in Section 7, “Diabetes Technology,” for more information on these systems.

Treatment of GDM with lifestyle and insulin has been demonstrated to improve perinatal outcomes in two large RCTs, as summarized in a U.S. Preventive Services Task Force review (97). Insulin is the first-line agent recommended for the treatment of GDM in the U.S. While individual studies support limited efficacy of metformin (98,99) and glyburide (100) in reducing glucose levels for the treatment of GDM, these agents are not recommended as the first-line treatment of GDM because they are known to cross the placenta and data on long-term safety for offspring is of some concern (39). Furthermore, in separate RCTs, glyburide and metformin failed to achieve adequate glycemic outcomes in 23% and 25–28% of participants with GDM, respectively (101,102).

#### **Sulfonylureas**

Sulfonylureas are known to cross the placenta and have been associated with increased neonatal hypoglycemia. Concentrations of glyburide in umbilical cord plasma are approximately 50–70% of maternal levels (101,102). In systematic reviews and meta-analyses, compared with insulin or metformin, glyburide was associated with a higher rate of neonatal hypoglycemia and macrosomia and an

increased neonatal abdominal circumference (103,104).

Glyburide was not found to be noninferior to insulin based on a composite outcome of neonatal hypoglycemia, macrosomia, and hyperbilirubinemia (105). Long-term safety data for offspring exposed to glyburide are not available (105).

#### **Metformin**

Metformin was associated with a lower risk of neonatal hypoglycemia and less maternal weight gain than insulin in systematic reviews and RCTs for GDM treatment, but treatment monotherapy failure occurred in 14–46% of individuals (103,106–109). A meta-analysis of 11 RCTs demonstrated that metformin treatment in pregnancy does not reduce the risk of GDM in high-risk individuals with obesity, polycystic ovary syndrome, or preexisting insulin resistance (110). RCTs of individuals with preexisting type 2 diabetes treated either with insulin alone or insulin plus metformin did not show differences in composite neonatal health outcomes between groups (111,112), and one of these also included individuals diagnosed with diabetes early in gestation (112). Neonatal birth weights were smaller in the metformin groups of these studies, but the metformin group experienced more drug intolerance in one study and there was a doubling of small-for-gestational-age neonates in the other (111,112). RCTs comparing metformin with other therapies for ovulation induction in individuals with polycystic ovary syndrome have not demonstrated benefit in preventing spontaneous abortion or GDM (113), and there is no evidence-based need to continue metformin in these individuals (114–116).

Of note, metformin readily crosses the placenta, resulting in umbilical cord blood levels of metformin as high or higher than simultaneous maternal levels (117,118). In the Metformin in Gestational Diabetes: The Offspring Follow-Up (MIG TOFU) study's analyses of 7- to 9-year-old offspring, the 9-year-old offspring exposed to metformin for the treatment of GDM in the Auckland cohort (but not the Adelaide cohort) were heavier and had a higher waist-to-height ratio and waist circumference than those exposed to insulin (119). In one RCT of metformin use in pregnancy for polycystic ovary syndrome, follow-up of 4-year-old offspring demonstrated higher BMI and increased obesity in the offspring exposed to metformin (120). A follow-up study at

5–10 years showed that the offspring had higher BMI, weight-to-height ratios, and waist circumferences and a borderline increase in fat mass (121,122). A meta-analysis demonstrated that metformin exposure resulted in smaller neonates with an acceleration of postnatal growth, resulting in higher BMI in childhood (121). Follow-up of offspring from the Metformin in Women with Type 2 Diabetes in Pregnancy (MiTy Kids) trial showed no differences in anthropometrics of children at 24 months (123).

There are some people with GDM requiring medical therapy who may not be able to use insulin safely or effectively during pregnancy due to cost, comprehension, or cultural influences. Oral agents may be an alternative for these individuals after discussing the known risks and the need for more long-term safety data in offspring. However, due to the potential for growth restriction or acidosis in the setting of placental insufficiency, metformin should not be used in pregnant people with hypertension or preeclampsia or those at risk for intrauterine growth restriction (123–125).

#### **Special Considerations for Management of Pregnancies With Diabetes**

Pregnant individuals with type 1 diabetes have an increased risk of hypoglycemia in the first trimester and after delivery, and like all pregnant people, they have altered counterregulatory response in pregnancy that may decrease hypoglycemia awareness. Education for people with diabetes and family members about the prevention, recognition, and treatment of hypoglycemia is important before, during, and after pregnancy to help prevent and manage hypoglycemia risk.

Pregnancy is a ketogenic state, and people with type 1 diabetes and, to a lesser extent, those with type 2 diabetes are at risk for diabetic ketoacidosis (DKA) at lower blood glucose levels than in the nonpregnant state. Pregnant people with type 1 diabetes should be advised to obtain ketone test strips and receive education on DKA prevention and detection. DKA carries a high risk of stillbirth. Those in DKA who are unable to eat often require 10% dextrose with an insulin drip to adequately meet the higher carbohydrate demands of the placenta and fetus in the third trimester to resolve their ketosis.

Retinopathy is a special concern in pregnancy. The necessary rapid implementation of euglycemia in the setting of retinopathy



is associated with worsening of retinopathy (126). Meta-analyses have also demonstrated a high risk of new-onset retinopathy and progression of existing retinopathy in pregnant individuals with type 1 or type 2 diabetes (32,127). Therefore, it is recommended that individuals with preexisting diabetes have dilated eye examinations before pregnancy, in each trimester of pregnancy, and for 1 year postpartum as indicated by the degree of retinopathy and as recommended by the eye care health care professional.

Recommended weight gain during pregnancy for people with overweight status is 15–25 lbs (6.8–11.3 kg) and for those with obesity is 10–20 lbs (4.5–9.1 kg) (69). There are no adequate data on optimal weight gain versus weight maintenance in pregnant people with BMI >35 kg/m<sup>2</sup>; however, losing weight is not recommended because of the increased risk of small-for-gestational-age infants (26).

## PREECLAMPSIA AND ASPIRIN

### Recommendation

**15.23** Pregnant individuals with type 1 or type 2 diabetes should be prescribed low-dose aspirin 100–150 mg/day starting at 12–16 weeks of gestation to lower the risk of preeclampsia. **E** A dosage of 162 mg/day may be acceptable; **E** currently, in the U.S., low-dose aspirin is available in 81-mg tablets.

Diabetes in pregnancy is associated with an increased risk of preeclampsia (128). The U.S. Preventive Services Task Force recommends that blood pressure measurements be obtained throughout gestation to screen for hypertensive disorders of pregnancy (129). The Task Force also recommends using low-dose aspirin (81 mg/day) as a preventive medication at 12 weeks of gestation in individuals at high risk for preeclampsia, such as those with type 1 or type 2 diabetes (130). However, a meta-analysis and an additional trial demonstrate that low-dose aspirin <100 mg is not effective in reducing preeclampsia, so a dose of >100 mg is required (131–133). A cost-benefit analysis has concluded that this approach would reduce morbidity, save lives, and lower health care costs (134). There are insufficient data about whether the use of aspirin specifically in pregnant people with preexisting diabetes ultimately reduces the

incidence of preeclampsia (135,136), although a meta-analysis showed that preeclampsia reductions occurred with aspirin administration in high-risk groups overall (128). Individuals with GDM may be candidates for aspirin therapy for preeclampsia prevention if they have a single high-risk factor, such as chronic hypertension or an autoimmune disease, or multiple moderate risk factors, such as being nulliparous, having obesity, being age ≥35 years, or other factors per the U.S. Preventive Services Task Force (130). More studies are needed to assess the long-term effects of prenatal aspirin exposure on offspring (135).

## PREGNANCY AND DRUG CONSIDERATIONS

### Recommendations

**15.24** In pregnant individuals with diabetes and chronic hypertension, a blood pressure threshold of 140/90 mmHg for initiation or titration of therapy is associated with better pregnancy outcomes than reserving treatment for severe hypertension, with no increase in risk of small-for-gestational-age birth weight. **A** There are limited data on the optimal lower limit, but therapy should be deintensified for blood pressure <90/60 mmHg. **E** A blood pressure goal of 110–135/85 mmHg is suggested in the interest of reducing the risk for accelerated maternal hypertension. **A**

**15.25a** Potentially harmful medications in pregnancy (e.g., ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists) should be stopped prior to conception and avoided in sexually active individuals of childbearing potential who are not using reliable contraception. **B**

**15.25b** In most circumstances, lipid-lowering medications should be stopped prior to conception and avoided in sexually active individuals of childbearing potential with diabetes who are not using reliable contraception. **B** In some circumstances (familial hypercholesterolemia, prior atherosclerotic cardiovascular disease event), statin therapy may be continued when the benefits outweigh risks. **E**

In normal pregnancy, blood pressure is lower than in the nonpregnant state. The

Chronic Hypertension and Pregnancy (CHAP) Trial Consortium's RCT on treatment of mild chronic hypertension during pregnancy demonstrated that a blood pressure of 140/90 mmHg, as the threshold for initiation or titration of treatment, reduces the incidence of adverse pregnancy outcomes without compromising fetal growth (137). The CHAP Consortium's study mitigates concerns about small-for-gestational-age birth weight. Attained mean ± SD blood pressure measurements in the treated versus untreated groups were systolic 129.5 ± 10.0 vs. 132.6 ± 10.1 mmHg (between-group difference −3.11 [95% CI −3.95 to 2.28]) and diastolic 79.1 ± 7.4 vs. 81.5 ± 8.0 mmHg (−2.33 [95% CI −2.97 to 0.04]), respectively (137). Individuals with diabetes had an even better composite outcome score than those without diabetes (137).

As a result of the CHAP study, ACOG issued a Practice Advisory recommending a blood pressure of 140/90 mmHg as the threshold for initiation or titration of medical therapy for chronic hypertension in pregnancy (138) rather than their previously recommended threshold of 160/110 mmHg (139).

Data from the previously published Control of Hypertension in Pregnancy Study (CHIPS) supports a blood pressure goal of 110–135/85 mmHg to reduce the risk of unmanaged maternal hypertension and minimize impaired fetal growth (139–141). The 2015 study (140) excluded pregnancies complicated by preexisting diabetes, and only 6% of participants had GDM at enrollment. There was no difference in pregnancy loss, neonatal care, or other neonatal outcomes between the groups with tighter versus less tight management of hypertension (140).

During pregnancy, treatment with ACE inhibitors and angiotensin receptor blockers is contraindicated because they may cause fetal renal dysplasia, oligohydramnios, pulmonary hypoplasia, and intrauterine growth restriction (30). A large study found that after adjusting for confounders, first-trimester ACE inhibitor exposure does not appear to be associated with congenital malformations (142). ACE inhibitors and angiotensin receptor blockers should be stopped prior to pregnancy or as soon as possible in the first trimester to avoid second- and third-trimester fetopathy (142). Antihypertensive drugs known to be effective and safe in pregnancy include methyldopa, nifedipine,

labetalol, and clonidine. Atenolol is not recommended, but other  $\beta$ -blockers may be used, if necessary. Diuretic use during pregnancy is generally not recommended, although it may be used safely when prescribed at lower doses for individuals in certain circumstances (e.g., chronic kidney disease and reduced glomerular filtration rate) (143).

For most individuals, lipid-lowering medications (e.g., bempedoic acid, PCSK9 therapies, fibrates) should be stopped prior to pregnancy or at the first pregnancy visit (31). Based on available evidence, statins should also be avoided in pregnancy in most circumstances (31). The risk of teratogenicity with statins appears to be low, but data are limited (31). Statins can be considered in a shared decision-making process between pregnant people with diabetes and their health care teams, including discussion of risks and benefits in pregnant individuals at high-risk, such as those with a history of atherosclerotic cardiovascular disease or familial hypercholesterolemia (homozygous or severe heterozygous) (31). Hydrophilic statins, such as pravastatin, may be associated with less fetal harm than lipophilic statins (144). Pravastatin has been studied in multiple pregnancy trials administering therapy at various time points in gestation with the aim to reduce preeclampsia risk, and although its ability to do so is inconclusive to date, there does not appear to be increased neonatal mortality or morbidity associated with its use during gestation (31). See pregnancy and antihypertensive medications in Section 10, "Cardiovascular Disease and Risk Management," for more information on managing blood pressure in pregnancy.

## POSTPARTUM CARE

### Recommendations

**15.26** Insulin requirements need to be evaluated and adjusted for individuals requiring insulin after delivery because insulin resistance decreases dramatically immediately postpartum. **C**

**15.27** A contraceptive plan should be discussed and implemented with all people with diabetes of childbearing potential. **A**

**15.28** Breastfeeding efforts are recommended for all individuals with diabetes. **A** Breastfeeding is recommended for individuals with a history of GDM for multiple benefits, **A** including a

reduced risk for type 2 diabetes later in life. **B**

**15.29** Postpartum care should include psychosocial assessment and support for self-care. **E**

**15.30** Screen individuals with a recent history of GDM at 4–12 weeks postpartum, using the 75-g oral glucose tolerance test and clinically appropriate nonpregnancy diagnostic criteria. **B**

**15.31** Individuals with a history of GDM should have lifelong screening for the development of type 2 diabetes or prediabetes every 1–3 years. **B**

**15.32** Individuals with overweight or obesity and a history of GDM found to have prediabetes should receive intensive lifestyle interventions and/or metformin to prevent diabetes. **A**

### Diabetes Treatment Postpartum

For individuals requiring insulin after delivery, insulin sensitivity increases dramatically with the delivery of the placenta. In one study, insulin requirements in the immediate postpartum period are roughly 34% lower than prepregnancy insulin requirements (145). Insulin sensitivity then returns to prepregnancy levels over the following 1–2 weeks. For individuals taking insulin, particular attention should be directed to hypoglycemia prevention in the setting of breastfeeding and erratic sleep and eating schedules (146). Individuals with GDM usually do not require diabetes medications in the postpartum period.

### Contraception

A major barrier to effective preconception care is the fact that the majority of pregnancies are unplanned. Planning pregnancy is critical in individuals with preexisting diabetes to achieve the optimal glycemic goals necessary to prevent congenital malformations and reduce the risk of other complications. Therefore, all individuals with diabetes of childbearing potential should have family planning options reviewed at regular intervals to make sure that effective contraception is implemented and maintained. This applies to individuals in the immediate postpartum period. Individuals with diabetes have the same contraception options and recommendations as those without diabetes, although the existence of diabetes complications or

other vascular disease may modify recommended options. Long-acting, reversible contraception may be ideal for individuals with diabetes and childbearing potential. The risk of an unplanned pregnancy outweighs the risk of any currently available contraception option.

### Lactation

Considering the immediate nutritional and immunological benefits of breastfeeding for the baby, all mothers, including those with diabetes, should be supported in attempts to breastfeed. An analysis of 28 systematic reviews and meta-analyses of associations between breastfeeding and outcomes in children found that breastfeeding was associated with numerous health benefits for children, such as reduced infant mortality due to infectious diseases at <6 months of age (OR 0.22–0.59 across studies), reduced respiratory infections in children aged <2 years, and reduced asthma or wheezing in children aged 5–18 years (OR 0.91, 0.85–0.98) (147). The same analysis found that breastfeeding was associated with improved maternal health outcomes, including reduced risks of breast cancer (OR 0.81 [95% CI 0.77–0.86]), ovarian cancer (OR 0.70 [95% CI 0.64–0.75]), and type 2 diabetes (OR 0.68 [95% CI 0.57–0.82]). Breastfeeding may also confer longer-term metabolic benefits to both mother (148) and offspring (149). Breastfeeding reduces the risk of developing type 2 diabetes in mothers with previous GDM (148). It may improve the metabolic risk factors of offspring, but more studies are needed (150). However, lactation can increase the risk of overnight hypoglycemia, and insulin dosing may need to be adjusted.

### Special Postpartum Considerations for Individuals With Gestational Diabetes Mellitus

Because GDM often represents previously undiagnosed prediabetes, type 2 diabetes, maturity-onset diabetes of the young, or even developing type 1 diabetes, individuals with GDM should be tested for persistent diabetes or prediabetes at 4–12 weeks postpartum with a fasting 75-g OGTT using nonpregnancy criteria as outlined in Section 2, "Diagnosis and Classification of Diabetes," specifically **Tables 2.1** and **2.2**. The OGTT is recommended over A1C at 4–12 weeks postpartum, because A1C may be persistently impacted (lowered) by the increased

red blood cell turnover related to pregnancy, by blood loss at delivery, or by the preceding 3-month glucose profile. The OGTT is more sensitive at detecting glucose intolerance, including both prediabetes and diabetes, and has been examined as a screening tool for these conditions in the first 12 weeks after delivery in individuals who had a recent pregnancy with GDM (151,152). In the absence of unequivocal hyperglycemia, a positive screen for diabetes requires two abnormal values. If both the fasting plasma glucose ( $\geq 126$  mg/dL [ $\geq 7.0$  mmol/L]) and 2-h plasma glucose ( $\geq 200$  mg/dL [ $\geq 11.1$  mmol/L]) are abnormal in a single screening test, then the diagnosis of diabetes is made. If only one abnormal value in the OGTT meets diabetes criteria, the test should be repeated to confirm that the abnormality persists. OGTT testing immediately postpartum, while still hospitalized, has demonstrated improved engagement in testing but also variably reduced sensitivity to the diagnosis of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes (153,154).

Individuals with a history of GDM should have ongoing screening for prediabetes or type 2 diabetes every 1–3 years, even if results of the initial 75-g OGTT at 4–12 weeks postpartum are normal. Ongoing evaluation may be performed with any recommended glycemic test (e.g., annual A1C, annual fasting plasma glucose, or triennial 75-g OGTT using thresholds for nonpregnant individuals).

Individuals with a history of GDM have an increased lifetime maternal risk for diabetes estimated at 50–60% (155,156), and those with GDM have a 10-fold increased risk of developing type 2 diabetes compared with those without GDM (155). Absolute risk of developing type 2 diabetes after GDM increases linearly through a person's lifetime, being ~20% at 10 years, 30% at 20 years, 40% at 30 years, 50% at 40 years, and 60% at 50 years (156). Hazard ratios for incident diabetes were significantly elevated for a history of GDM in a single pregnancy but were even higher for a history of two GDM pregnancies in a large retrospective cohort study (hazard ratios ranged from 4.35- to 15.8-fold based on number of pregnancies with GDM and in which pregnancy the individual had GDM (first or second) (157). In the prospective Nurses' Health Study II (NHS II), subsequent diabetes risk after a history of GDM was significantly lower in those who followed healthy eating patterns (158).

Adjusting for BMI moderately attenuated this association. Interpregnancy weight gain is associated with increased risk of adverse pregnancy outcomes (159) and higher risk of GDM, while in people with BMI  $> 25$  kg/m<sup>2</sup>, weight loss is associated with lower risk of developing GDM in the subsequent pregnancy (160). Development of type 2 diabetes is 18% higher per unit of BMI increase from prepregnancy BMI at follow-up, highlighting the importance of effective weight management after GDM (161). In addition, postdelivery lifestyle interventions are effective in reducing risk of type 2 diabetes (162).

Both metformin and intensive lifestyle intervention prevent or delay progression to diabetes in individuals with prediabetes and a history of GDM. Only five to six individuals with prediabetes and a history of GDM need to be treated with either intervention to prevent one case of diabetes over 3 years (163). In these individuals, lifestyle intervention and metformin reduced progression to diabetes by 35% and 40%, respectively, over 10 years compared with placebo (164). If the pregnancy has motivated the adoption of healthy nutrition, building on these gains to support weight loss is recommended in the postpartum period (see Section 3, "Prevention or Delay of Diabetes and Associated Comorbidities").

## References

- Dabelea D, Hanson RL, Lindsay RS, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. *Diabetes* 2000;49:2208–2211
- Holmes VA, Young IS, Patterson CC, et al.; Diabetes and Pre-eclampsia Intervention Trial Study Group. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. *Diabetes Care* 2011;34:1683–1688
- Wahabi HA, Fayed A, Esmail S, et al. Systematic review and meta-analysis of the effectiveness of pre-pregnancy care for women with diabetes for improving maternal and perinatal outcomes. *PLoS One* 2020;15:e0237571
- Charron-Prochownik D, Sereika SM, Becker D, et al. Long-term effects of the booster-enhanced READY-Girls preconception counseling program on intentions and behaviors for family planning in teens with diabetes. *Diabetes Care* 2013;36:3870–3874
- ACOG Committee Opinion No. 762: Pre-pregnancy Counseling. *Obstet Gynecol* 2019;133:e78–e89
- Peterson C, Grosse SD, Li R, et al. Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. *Am J Obstet Gynecol* 2015;212:74.e1–e9
- Britton LE, Hussey JM, Berry DC, Crandell JL, Brooks JL, Bryant AG. Contraceptive use among women with prediabetes and diabetes in a US national sample. *J Midwifery Womens Health* 2019;64:36–45
- Morris JR, Tepper NK. Description and comparison of postpartum use of effective contraception among women with and without diabetes. *Contraception* 2019;100:474–479
- Goldstuck ND, Steyn PS. The intrauterine device in women with diabetes mellitus type I and II: a systematic review. *ISRN Obstet Gynecol* 2013;2013:814062
- Wu JP, Moniz MH, Ursu AN. Long-acting reversible contraception—highly efficacious, safe, and underutilized. *JAMA* 2018;320:397–398
- American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. *Obstet Gynecol* 2018;132:e228–e248
- Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. *Diabetes Care* 2007;30:1920–1925
- Jensen DM, Korsholm L, Ovesen P, et al. Periconceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. *Diabetes Care* 2009;32:1046–1048
- Nielsen GL, Møller M, Sørensen HT. HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. *Diabetes Care* 2006;29:2612–2616
- Ludvigsson JF, Neovius M, Söderling J, et al. Maternal glycemic control in type 1 diabetes and the risk for preterm birth: a population-based cohort study. *Ann Intern Med* 2019;170:691–701
- Ludvigsson JF, Neovius M, Söderling J, et al. Periconception glycaemic control in women with type 1 diabetes and risk of major birth defects: population based cohort study in Sweden. *BMJ* 2018;362:k2638
- Wahabi HA, Alzeidan RA, Bawazeer GA, Alansari LA, Esmail SA. Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis. *BMC Pregnancy Childbirth* 2010;10:63
- American Diabetes Association. Reproductive Health for Teen Girls with Diabetes. Accessed 25 August 2024. Available from <https://diabetes.org/health-wellness/sexual-health/reproductive-health-teen-girls-diabetes>
- Phelan S, Jelalian E, Coustan D, et al. Randomized controlled trial of prepregnancy lifestyle intervention to reduce recurrence of gestational diabetes mellitus. *Am J Obstet Gynecol* 2023;229:158.e151–158.e114
- Barry MJ, Nicholson WK, Silverstein M, et al.; US Preventive Services Task Force. Folic acid supplementation to prevent neural tube defects: US Preventive Services Task Force reaffirmation recommendation statement. *JAMA* 2023;330:454–459
- Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid* 2017;27:315–389

22. Ramos DE. Preconception health: changing the paradigm on well-woman health. *Obstet Gynecol Clin North Am* 2019;46:399–408
23. Metzger BE, Lowe LP, Dyer AR, et al.; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med* 2008;358:1991–2002
24. Scholtens DM, Kuang A, Lowe LP, et al.; HAPO Follow-Up Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): maternal glycemia and childhood glucose metabolism. *Diabetes Care* 2019;42:381–392
25. Lowe WL, Scholtens DM, Kuang A, et al.; HAPO Follow-up Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): maternal gestational diabetes mellitus and childhood glucose metabolism. *Diabetes Care* 2019;42:372–380
26. Obesity in pregnancy: ACOG Practice Bulletin, Number 230. *Obstet Gynecol* 2021;137:e128–e144
27. Clausen TD, Mathiesen E, Ekbohm P, Hellmuth E, Mandrup-Poulsen T, Damm P. Poor pregnancy outcome in women with type 2 diabetes. *Diabetes Care* 2005;28:323–328
28. Cundy T, Gamble G, Neale L, et al. Differing causes of pregnancy loss in type 1 and type 2 diabetes. *Diabetes Care* 2007;30:2603–2607
29. Relph S, Patel T, Delaney L, Sobhy S, Thangaratnam S. Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: a systematic review and meta-analysis. *PLoS Med* 2021;18:e1003856
30. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. *Hypertension* 2012;60:444–450
31. Agarwala A, Dixon DL, Gianos E, et al. Dyslipidemia management in women of reproductive potential: an expert clinical consensus from the national lipid association. *J Clin Lipidol*. 30 May 2024 [Epub ahead of print].
32. Widyaputri F, Rogers S, Lim L. Global estimates of diabetic retinopathy prevalence and progression in pregnant individuals with preexisting diabetes: a meta-analysis. *JAMA Ophthalmol* 2022;140:1137–1138
33. García-Patterson A, Gich I, Amini SB, Catalano PM, de Leiva A, Corcoy R. Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction. *Diabetologia* 2010;53:446–451
34. Mathiesen JM, Secher AL, Ringholm L, et al. Changes in basal rates and bolus calculator settings in insulin pumps during pregnancy in women with type 1 diabetes. *J Matern Fetal Neonatal Med* 2014;27:724–728
35. Best Practice Guide: using diabetes technology in pregnancy. 2020. Accessed 11 August 2024. Available from [https://abcd.care/sites/abcd.care/files/site\\_uploads/Resources/DTN/BP-Pregnancy-DTN-V2.0.pdf](https://abcd.care/sites/abcd.care/files/site_uploads/Resources/DTN/BP-Pregnancy-DTN-V2.0.pdf)
36. Padmanabhan S, Lee VW, Mclean M, et al. The association of falling insulin requirements with maternal biomarkers and placental dysfunction: a prospective study of women with preexisting diabetes in pregnancy. *Diabetes Care* 2017;40:1323–1330
37. de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. *N Engl J Med* 1995;333:1237–1241
38. Jovanovic-Peterson L, Peterson CM, Reed GF, et al. Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development-Diabetes in Early Pregnancy Study. *Am J Obstet Gynecol* 1991;164:103–111
39. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. *Obstet Gynecol* 2018;131:e49–e64
40. Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged? *Diabetes Care* 2011;34:1660–1668
41. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. *Diabetes Care* 2019;42:1593–1603
42. Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. *Diabetes Care* 2007;30(Suppl 2):S251–S260
43. Ho Y-R, Wang P, Lu M-C, Tseng S-T, Yang C-P, Yan Y-H. Associations of mid-pregnancy HbA1c with gestational diabetes and risk of adverse pregnancy outcomes in high-risk Taiwanese women. *PLoS One* 2017;12:e0177563
44. Maresh MJA, Holmes VA, Patterson CC, et al.; Diabetes and Pre-eclampsia Intervention Trial Study Group. Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. *Diabetes Care* 2015;38:34–42
45. Nielsen LR, Ekbohm P, Damm P, et al. HbA1c levels are significantly lower in early and late pregnancy. *Diabetes Care* 2004;27:1200–1201
46. Mosca A, Paleari R, Dalfrà MG, et al. Reference intervals for hemoglobin A1c in pregnant women: data from an Italian multicenter study. *Clin Chem* 2006;52:1138–1143
47. Hummel M, Marienfeld S, Huppman M, et al. Fetal growth is increased by maternal type 1 diabetes and HLA DR4-related gene interactions. *Diabetologia* 2007;50:850–858
48. Cyganek K, Skupien J, Katra B, et al. Risk of macrosomia remains glucose-dependent in a cohort of women with pregestational type 1 diabetes and good glycemic control. *Endocrine* 2017;55:447–455
49. Abell SK, Boyle JA, de Courten B, et al. Impact of type 2 diabetes, obesity and glycaemic control on pregnancy outcomes. *Aust N Z J Obstet Gynaecol* 2017;57:308–314
50. Temple RC, Aldridge V, Stanley K, Murphy HR. Glycaemic control throughout pregnancy and risk of pre-eclampsia in women with type 1 diabetes. *BJOG* 2006;113:1329–1332
51. Combs CA, Gunderson E, Kitzmiller JL, Gavin LA, Main EK. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. *Diabetes Care* 1992;15:1251–1257
52. Langer O, Levy J, Brustman L, Anyaegbunam A, Merkatz R, Divon M. Glycemic control in gestational diabetes mellitus—how tight is tight enough: small for gestational age versus large for gestational age? *Am J Obstet Gynecol* 1989;161:646–653
53. Feig DS, Donovan LE, Corcoy R, et al.; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. *Lancet* 2017;390:2347–2359
54. Kristensen K, Ögge LE, Sengpiel V, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. *Diabetologia* 2019;62:1143–1153
55. Law GR, Gilthorpe MS, Secher AL, et al. Translating HbA1c measurements into estimated average glucose values in pregnant women with diabetes. *Diabetologia* 2017;60:618–624
56. Sanusi AA, Xue Y, McIlwraith C, et al. Association of continuous glucose monitoring metrics with pregnancy outcomes in patients with preexisting diabetes. *Diabetes Care* 2024;47:89–96
57. Ahmed RJ, Gafni A, Hutton EK, et al.; CONCEPTT Collaborative Group. The cost implications of continuous glucose monitoring in pregnant women with type 1 diabetes in 3 Canadian provinces: a posthoc cost analysis of the CONCEPTT trial. *CMAJ Open* 2021;9:E627–E634
58. García-Moreno RM, Benítez-Valderrama P, Barquiel B, et al. Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. *Diabet Med* 2022;39:e14703
59. Wyckoff JA, Brown FM. Time in range in pregnancy: is there a role? *Diabetes Spectr* 2021;34:119–132
60. Nørgaard SK, Mathiesen ER, Nørgaard K, Ringholm L. Comparison of glycemic metrics measured simultaneously by intermittently scanned continuous glucose monitoring and real-time continuous glucose monitoring in pregnant women with type 1 diabetes. *Diabetes Technol Ther* 2021;23:665–672
61. Neoh SL, Grisoni JA, Feig DS, Murphy HR, CONCEPTT Collaborative Group. Dietary intakes of women with type 1 diabetes before and during pregnancy: a pre-specified secondary subgroup analysis among CONCEPTT participants. *Diabet Med* 2020;37:1841–1848
62. Marshall NE, Abrams B, Barbour LA, et al. The importance of nutrition in pregnancy and lactation: lifelong consequences. *Am J Obstet Gynecol* 2022;226:607–632
63. US Department of Agriculture; US Department of Health and Human Services. Dietary Guidelines for Americans, 2020–2025. Diet and Health Relationships: Pregnancy and Lactation. Accessed 12 August 2024. Available from [https://www.dietaryguidelines.gov/sites/default/files/2020-12/Dietary\\_Guidelines\\_for\\_Americans\\_2020-2025.pdf](https://www.dietaryguidelines.gov/sites/default/files/2020-12/Dietary_Guidelines_for_Americans_2020-2025.pdf)
64. *Dietary Reference Intakes: The Essential Guide to Nutrient Requirements*. The National Academies Press, 2006. Accessed 30 October 2024. Available from <https://nap.nationalacademies.org/catalog/11537/dietary-reference-intakes-the-essential-guide-to-nutrient-requirements>
65. Hernandez TL, Mande A, Barbour LA. Nutrition therapy within and beyond gestational diabetes. *Diabetes Res Clin Pract* 2018;145:39–50
66. Hernandez TL, Van Pelt RE, Anderson MA, et al. A higher-complex carbohydrate diet in

- gestational diabetes mellitus achieves glucose targets and lowers postprandial lipids: a randomized crossover study. *Diabetes Care* 2014;37:1254–1262
67. Han S, Middleton P, Shepherd E, Van Ryswyk E, Crowther CA. Different types of dietary advice for women with gestational diabetes mellitus. *Cochrane Database Syst Rev* 2017;2:CD009275
68. Viana LV, Gross JL, Azevedo MJ. Dietary intervention in patients with gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials on maternal and newborn outcomes. *Diabetes Care* 2014;37:3345–3355
69. *Weight Gain During Pregnancy: Reexamining the Guidelines*. Rasmussen KM, Yaktine AL, Eds. Washington, DC, 2009. Accessed 16 October 2024. Available from <https://nap.nationalacademies.org/catalog/12584/weight-gain-during-pregnancy-reexamining-the-guidelines>
70. Koivusalo SB, Rönö K, Klemetti MM, et al. Gestational diabetes mellitus can be prevented by lifestyle intervention: the Finnish Gestational Diabetes Prevention Study (RADIEL). A randomized controlled trial. *Diabetes Care* 2016;39:24–30
71. Wang C, Wei Y, Zhang X, et al. A randomized clinical trial of exercise during pregnancy to prevent gestational diabetes mellitus and improve pregnancy outcome in overweight and obese pregnant women. *Am J Obstet Gynecol* 2017;216:340–351
72. Griffith RJ, Alsweiler J, Moore AE, et al. Interventions to prevent women from developing gestational diabetes mellitus: an overview of Cochrane Reviews. *Cochrane Database Syst Rev* 2020;6:CD012394
73. Mayo K, Melamed N, Vandenberghe H, Berger H. The impact of adoption of the international association of diabetes in pregnancy study group criteria for the screening and diagnosis of gestational diabetes. *Am J Obstet Gynecol* 2015;212:e221–e224
74. U.S. Department of Health and Human Services. *Physical Activity Guidelines for Americans*, 2nd edition, 2018. Accessed 12 August 2024. Available from [https://health.gov/sites/default/files/2019-09/Physical\\_Activity\\_Guidelines\\_2nd\\_edition.pdf](https://health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_edition.pdf)
75. Laredo-Aguilera JA, Gallardo-Bravo M, Rabanales-Sotos JA, Cobo-Cuenca AI, Carmona-Torres JM. Physical activity programs during pregnancy are effective for the control of gestational diabetes mellitus. *Int J Environ Res Public Health* 2020;17:6151
76. Xie W, Dai P, Qin Y, Wu M, Yang B, Yu X. Effectiveness of telemedicine for pregnant women with gestational diabetes mellitus: an updated meta-analysis of 32 randomized controlled trials with trial sequential analysis. *BMC Pregnancy Childbirth* 2020;20:198
77. Ram M, Feinmesser L, Shinar S, Maslovitz S. The importance of declining insulin requirements during pregnancy in patients with pre-gestational gestational diabetes mellitus. *Eur J Obstet Gynecol Reprod Biol* 2017;215:148–152
78. Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin glargine safety in pregnancy: a transplacental transfer study. *Diabetes Care* 2010;33:29–33
79. Holcberg G, Tsadkin-Tamir M, Sapir O, et al. Transfer of insulin lispro across the human placenta. *Eur J Obstet Gynecol Reprod Biol* 2004;115:117–118
80. Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. *Diabetes Care* 2003;26:1390–1394
81. McCance DR, Damm P, Mathiesen ER, et al. Evaluation of insulin antibodies and placental transfer of insulin aspart in pregnant women with type 1 diabetes mellitus. *Diabetologia* 2008;51:2141–2143
82. Farrar D, Tuffnell DJ, West J, West HM. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. *Cochrane Database Syst Rev* 2016;2016:CD005542
83. Suffecool K, Rosenn B, Niederkofler EE, et al. Insulin detemir does not cross the human placenta. *Diabetes Care* 2015;38:e20–e21
84. O'Neill SM, Kenny LC, Khashan AS, West HM, Smyth RM, Kearney PM. Different insulin types and regimens for pregnant women with pre-existing diabetes. *Cochrane Database Syst Rev* 2017;2:CD011880
85. Fishel Bartal M, Ward C, Blackwell SC, et al. Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial. *Am J Obstet Gynecol* 2021;225:87:e81–e87
86. Mathiesen ER, Alibegovic AC, Corcoy R, et al.; EXPECT Study Group. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial. *Lancet Diabetes Endocrinol* 2023;11:86–95
87. Pollex E, Moretti ME, Koren G, Feig DS. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. *Ann Pharmacother* 2011;45:9–16
88. Kernaghan D, Farrell T, Hammond P, Owen P. Fetal growth in women managed with insulin pump therapy compared to conventional insulin. *Eur J Obstet Gynecol Reprod Biol* 2008;137:47–49
89. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial. *Diabetes Care* 2018;41:2155–2161
90. Lee TTM, Collett C, Bergford S, et al.; AiDAPT Collaborative Group. Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. *N Engl J Med* 2023;389:1566–1578
91. Lawton J, Kimbell B, Closs M, et al. Listening to women: experiences of using closed-loop in type 1 diabetes pregnancy. *Diabetes Technol Ther* 2023;25:845–855
92. Benhalima K, Beunen K, Van Wilder N, et al. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial. *Lancet Diabetes Endocrinol* 2024;12:390–403
93. Polsky S, Buschur E, Dungan K, et al. Randomized trial of assisted hybrid closed-loop therapy versus sensor-augmented pump therapy in pregnancy. *Diabetes Technol Ther* 2024;26:547–555
94. Szmuiłowicz ED, Levy CJ, Buschur EO, Polsky S. Expert guidance on off-label use of hybrid closed-loop therapy in pregnancies complicated by diabetes. *Diabetes Technol Ther* 2023;25:363–373
95. Wilkie GL, Delpapa E, Leftwich HK. Intrapartum continuous subcutaneous insulin infusion vs intravenous insulin infusion among pregnant individuals with type 1 diabetes mellitus: a randomized controlled trial. *Am J Obstet Gynecol* 2023;229:680.e681–680.e688
96. Donovan LE, Feig DS, Lemieux P, et al. A randomized trial of closed-loop insulin delivery postpartum in type 1 diabetes. *Diabetes Care* 2023;46:2258–2266
97. Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. *Ann Intern Med* 2013;159:123–129
98. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. *N Engl J Med* 2008;358:2003–2015
99. Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. *PLoS One* 2013;8:e64585
100. Song R, Chen L, Chen Y, et al. Comparison of glyburide and insulin in the management of gestational diabetes: a meta-analysis. *PLoS One* 2017;12:e0182488
101. Hebert MF, Ma X, Naraharsetti SB, et al.; Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. *Clin Pharmacol Ther* 2009;85:607–614
102. Malek R, Davis SN. Pharmacokinetics, efficacy and safety of glyburide for treatment of gestational diabetes mellitus. *Expert Opin Drug Metab Toxicol* 2016;12:691–699
103. Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. *BMJ* 2015;350:h102
104. Tarry-Adkins JL, Aiken CE, Ozanne SE. Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: a systematic review and meta-analysis. *PLoS Med* 2020;17:e1003126
105. Sénat M-V, Affres H, Letourneau A, et al.; Groupe de Recherche en Obstétrique et Gynécologie (GROG). Effect of glyburide vs subcutaneous insulin on perinatal complications among women with gestational diabetes: a randomized clinical trial. *JAMA* 2018;319:1773–1780
106. Silva JC, Pacheco C, Bizato J, de Souza BV, Ribeiro TE, Bertini AM. Metformin compared with glyburide for the management of gestational diabetes. *Int J Gynaecol Obstet* 2010;111:37–40
107. Nachum Z, Zafran N, Salim R, et al. Glyburide versus metformin and their combination for the treatment of gestational diabetes mellitus: a randomized controlled study. *Diabetes Care* 2017;40:332–337
108. Jiang Y-F, Chen X-Y, Ding T, Wang X-F, Zhu Z-N, Su S-W. Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab* 2015;100:2071–2080
109. Dunne F, Newman C, Alvarez-Iglesias A, et al. Early metformin in gestational diabetes: a

- randomized clinical trial. *JAMA* 2023;330:1547–1556
110. Doi SAR, Furuya-Kanamori L, Toft E, et al. Metformin in pregnancy to avert gestational diabetes in women at high risk: meta-analysis of randomized controlled trials. *Obes Rev* 2020; 21:e12964
  111. Feig DS, Donovan LE, Zinman B, et al.; MiTy Collaborative Group. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol* 2020;8:834–844
  112. Boggess KA, Valint A, Refuerzo JS, et al. Metformin plus insulin for preexisting diabetes or gestational diabetes in early pregnancy: the MOMPOD randomized clinical trial. *JAMA* 2023; 330:2182–2190
  113. Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. *J Clin Endocrinol Metab* 2010;95:E448–E455
  114. Palomba S, Orio F, Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2005;90:4068–4074
  115. Palomba S, Orio F, Nardo LG, et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. *J Clin Endocrinol Metab* 2004;89:4801–4809
  116. Legro RS, Barnhart HX, Schlaff WD, et al.; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. *N Engl J Med* 2007;356:551–566
  117. Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. *Fertil Steril* 2005;83: 1575–1578
  118. Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. *Ther Drug Monit* 2006;28:67–72
  119. Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age. *BMJ Open Diabetes Res Care* 2018;6:e000456
  120. Hanem LGE, Stridsklev S, Júliusson PB, et al. Metformin use in PCOS pregnancies increases the risk of offspring overweight at 4 years of age: follow-up of two RCTs. *J Clin Endocrinol Metab* 2018;103:1612–1621
  121. Tarry-Adkins JL, Aiken CE, Ozanne SE. Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: a systematic review and meta-analysis. *PLoS Med* 2019;16:e1002848
  122. Hanem LGE, Salvesen Ø, Júliusson PB, et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5–10 year follow-up of the PregMet randomised controlled trial. *Lancet Child Adolesc Health* 2019;3:166–174
  123. Feig DS, Sanchez JJ, Murphy KE, et al.; MiTy Kids Collaborative Group. Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. *Lancet Diabetes Endocrinol* 2023;11:191–202
  124. Barbour LA, Feig DS. Metformin for Gestational Diabetes Mellitus: Progeny, Perspective, and a Personalized Approach. *Diabetes Care* 2019; 42:396–399
  125. Barbour LA, Scifres C, Valent AM, et al. A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes. *American Journal of Obstetrics and Gynecology* 2018;219:367.e1–367.e7
  126. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. *Diabetes Care* 1995;18:631–637
  127. Sarvepalli SM, Bailey BA, D'Alessio D, et al. Risk factors for the development or progression of diabetic retinopathy in pregnancy: meta-analysis and systematic review. *Clin Exp Ophthalmol* 2023; 51:195–204
  128. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. *Bmj* 2005;330:565
  129. Barry MJ, Nicholson WK, Silverstein M, et al.; US Preventive Services Task Force. Screening for hypertensive disorders of pregnancy: US Preventive Services Task Force final recommendation statement. *JAMA* 2023;330:1074–1082
  130. Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. *Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the US Preventive Services Task Force*. Rockville, MD, Agency for Healthcare Research and Quality, 2014. Accessed 16 October 2024. Available from <https://www.ncbi.nlm.nih.gov/books/NBK196392/>
  131. Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. *Am J Obstet Gynecol* 2018;218:287–293
  132. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. *N Engl J Med* 2017;377: 613–622
  133. Hoffman MK, Goudar SS, Kodkany BS, et al.; ASPIRIN Study Group. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. *Lancet* 2020;395:285–293
  134. Werner EF, Hauspurg AK, Rouse DJ. A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. *Obstet Gynecol* 2015;126:1242–1250
  135. Zen M, Haider R, Simmons D, et al. Aspirin for the prevention of pre-eclampsia in women with pre-existing diabetes: systematic review. *Aust N Z J Obstet Gynaecol* 2022;62:12–21
  136. Voutetakis A, Pervanidou P, Kanaka-Gantenbein C. Aspirin for the prevention of preeclampsia and potential consequences for fetal brain development. *JAMA Pediatr* 2019;173:619–620
  137. Tita AT, Szychowski JM, Boggess K, et al.; Chronic Hypertension and Pregnancy (CHAP) Trial Consortium. Treatment for mild chronic hypertension during pregnancy. *N Engl J Med* 2022; 386:1781–1792
  138. American College of Obstetricians and Gynecologists. Clinical guidance for the integration of the findings of the Chronic Hypertension and Pregnancy (CHAP) study. 2022. Accessed 31 August 2024. Available from <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/04/clinical-guidance-for-the-integration-of-the-findings-of-the-chronic-hypertension-and-pregnancy-chap-study>
  139. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. *Obstet Gynecol* 2019; 133:e26–e50
  140. Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. *N Engl J Med* 2015;372:407–417
  141. Brown MA, Magee LA, Kenny LC, et al.; International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. *Hypertension* 2018;72:24–43
  142. Bateman BT, Patorno E, Desai RJ, et al. Angiotensin-converting enzyme inhibitors and the risk of congenital malformations. *Obstet Gynecol* 2017;129:174–184
  143. Garovic VD, Dechend R, Easterling T, et al.; American Heart Association Council on Hypertension; Council on the Kidney in Cardiovascular Disease, Kidney in Heart Disease Science Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; Stroke Council. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. *Hypertension* 2022;79:e21–e41
  144. Chang J-C, Chen Y-J, Chen I-C, Lin W-S, Chen Y-M, Lin C-H. Perinatal outcomes after statin exposure during pregnancy. *JAMA Netw Open* 2021;4:e2141321
  145. Achong N, Duncan EL, McIntyre HD, Callaway L. Peripartum management of glycemia in women with type 1 diabetes. *Diabetes Care* 2014;37:364–371
  146. Riviello C, Mello G, Jovanovic LG. Breastfeeding and the basal insulin requirement in type 1 diabetic women. *Endocr Pract* 2009;15:187–193
  147. Victora CG, Bahl R, Barros AJD, et al.; Lancet Breastfeeding Series Group. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. *Lancet* 2016;387:475–490
  148. Stuebe AM, Rich-Edwards JW, Willett WC, Manson JE, Michels KB. Duration of lactation and incidence of type 2 diabetes. *JAMA* 2005;294:2601–2610
  149. Pereira PF, Alfenas RdCG, Araújo RMA. Does breastfeeding influence the risk of developing diabetes mellitus in children? A review of current evidence. *J Pediatr (Rio J)* 2014;90:7–15
  150. Pathirana MM, Ali A, Lassi ZS, Arstall MA, Roberts CT, Andraweera PH. Protective influence of breastfeeding on cardiovascular risk factors in women with previous gestational diabetes mellitus and their children: a systematic review and meta-analysis. *J Hum Lact* 2022;38:501–512
  151. Noctor E, Crowe C, Carmody LA, et al.; ATLANTIC-DIP Investigators. Abnormal glucose tolerance post-gestational diabetes mellitus as defined by the International Association of Diabetes and Pregnancy Study Groups criteria. *Eur J Endocrinol* 2016;175:287–297

152. Liu Z, Zhang Q, Liu L, Liu W. Risk factors associated with early postpartum glucose intolerance in women with a history of gestational diabetes mellitus: a systematic review and meta-analysis. *Endocrine* 2023;82:498–512
153. Waters TP, Kim SY, Werner E, et al. Should women with gestational diabetes be screened at delivery hospitalization for type 2 diabetes? *Am J Obstet Gynecol* 2020;222:e71
154. Werner EF, Has P, Rouse D, Clark MA. Two-day postpartum compared with 4- to 12-week postpartum glucose tolerance testing for women with gestational diabetes. *Am J Obstet Gynecol* 2020;223:e431–e437
155. Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. *BMJ* 2020;369:m1361
156. Li Z, Cheng Y, Wang D, et al. Incidence rate of type 2 diabetes mellitus after gestational diabetes mellitus: a systematic review and meta-analysis of 170,139 women. *J Diabetes Res* 2020;2020:3076463
157. Mussa J, Rahme E, Dahhou M, Nakhla M, Dasgupta K. Incident diabetes in women with patterns of gestational diabetes occurrences across 2 pregnancies. *JAMA Netw Open* 2024;7:e2410279
158. Tobias DK, Hu FB, Chavarro J, Rosner B, Mozaffarian D, Zhang C. Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus. *Arch Intern Med* 2012;172:1566–1572
159. Villamor E, Cnattingius S. Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-based study. *Lancet* 2006;368:1164–1170
160. Martínez-Hortelano JA, Cavero-Redondo I, Álvarez-Bueno C, Díez-Fernández A, Hernández-Luengo M, Martínez-Vizcaíno V. Interpregnancy weight change and gestational diabetes mellitus: a systematic review and meta-analysis. *Obesity (Silver Spring)* 2021;29:454–464
161. Dennison RA, Chen ES, Green ME, et al. The absolute and relative risk of type 2 diabetes after gestational diabetes: a systematic review and meta-analysis of 129 studies. *Diabetes Res Clin Pract* 2021;171:108625
162. Li N, Yang Y, Cui D, et al. Effects of lifestyle intervention on long-term risk of diabetes in women with prior gestational diabetes: a systematic review and meta-analysis of randomized controlled trials. *Obes Rev* 2021;22:e13122
163. Ratner RE, Christophi CA, Metzger BE, et al.; Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin Endocrinol Metab* 2008;93:4774–4779
164. Aroda VR, Christophi CA, Edelstein SL, et al.; Diabetes Prevention Program Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. *J Clin Endocrinol Metab* 2015;100:1646–1653
165. ACOG Committee Opinion No. 741: Maternal Immunization. *Obstet Gynecol* 2018;131:e214–e217
166. Maternal Immunization Practice Advisory October 2022 website. Accessed 7 August 2024. Available from <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/10/maternal-immunization>
167. Viral Hepatitis in Pregnancy: ACOG Clinical Practice Guideline No. 6. *Obstet Gynecol* 2023;142:745–759